Quantum BioPharma Ltd. (NASDAQ: QNTM) has entered into a Study Start-Up Agreement (SUA) with the clinical research business of Thermo Fisher Scientific to implement its Phase 2 clinical trial of Lucid-21-302, also known as Lucid-MS, for multiple sclerosis (MS). The agreement initiates formal study start-up activities following FDA clearance to proceed with the trial, according to a Quantum BioPharma (NASDAQ: QNTM) announcement.
Thermo Fisher will support study start-up and related clinical research services through its PPD Clinical Research Business. The randomized, double-blind, placebo-controlled Phase 2 trial will evaluate the efficacy, safety, and tolerability of Lucid-MS in people with progressive forms of MS using clinical and radiological endpoints.
Lucid-MS is an investigational, first-in-class New Chemical Entity designed to provide neuroprotection by inhibiting demyelination through targeting protein arginine deiminase 2 (PAD2), an enzyme implicated in myelin degradation. This mechanism of action distinguishes it from existing MS therapies, which primarily modulate the immune system rather than directly protect myelin.
The importance of this development lies in its potential to address a significant unmet need. Progressive forms of MS currently have limited treatment options, and Lucid-MS represents a novel approach that could prevent or reverse myelin degradation, the underlying mechanism of the disease. Preclinical models have shown that Lucid-MS can prevent and reverse myelin degradation, offering hope for a disease-modifying therapy.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of its lead compound, Lucid-MS.
The company also invented UNBUZZD and spun out its OTC version to Unbuzzd Wellness Inc., led by industry veterans. Quantum retains ownership of 19.84% (as of March 31, 2026) of Unbuzzd. The agreement includes royalty payments of 7% of sales until payments to Quantum total $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.
For investors, this agreement signals tangible progress in Quantum’s clinical pipeline and validates the potential of Lucid-MS. The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM. To view the full press release, visit https://ibn.fm/CZH9U.
BioMedWire is a specialized communications platform with a focus on the latest developments in the Biotechnology, Biomedical Sciences, and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions.
